Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020

J Rheumatol. 2021 Nov;48(11):1755-1756. doi: 10.3899/jrheum.210537. Epub 2021 Sep 1.

Authors

Arielle Mendel¹, Christian Pagnoux²

Affiliations

¹ Division of Rheumatology, McGill University Health Centre and Centre for Outcomes Research and Evaluation, Montreal, Quebec; arielle.mendel@mcgill.ca.
² Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

PMID: 34470792
DOI: 10.3899/jrheum.210537

No abstract available

Publication types

Letter

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Canada
Humans
Rituximab* / therapeutic use

Substances

Rituximab